Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial

What Was Tested

Researchers studied Teriparatide in this randomized controlled trial publication.

Primary objective was to compare lumbar spine (L1 -L3 ) BMD measured by quantitative computed tomography (QCT).

A mixed model repeated measures analysis was performed to compare changes from baseline between groups.

Why It Was Studied

Data on treatment of glucocorticoid-induced osteoporosis (GIO) in men are scarce.

The researchers performed a randomized, open-label trial in men who have taken glucocorticoids (GC) for ≥3 months, and had an areal bone mineral density (aBMD) T-score ≤ -1.5 standard deviations.

Who Took Part

The age groups tagged for this paper are adults, middle-aged adults, older adults and people over 80, women only.

How the Study Was Run

In design terms this was a randomized and open-label study.

Random assignment meant chance, not the researchers, decided who got Teriparatide and who got the comparison, which limits bias.

Being open-label, the Teriparatide study did not mask who received what.

A time span of 18 months appears in the methods.

What Was Measured

The researchers performed a randomized, open-label trial in men who have taken glucocorticoids (GC) for ≥3 months, and had an areal bone mineral density (aBMD) T-score ≤ -1.5 standard deviations.

Secondary outcomes included BMD and microstructure measured by high-resolution QCT (HRQCT) at the 12th thoracic vertebra, biomechanical effects for axial compression, anterior bending, and axial torsion evaluated by finite element (FE) analysis from HRQCT data, aBMD by dual X-ray absorptiometry, biochemical markers, and safety.

The subject headings attached to it are Bone Density, Bone Density Conservation Agents, Etidronic Acid, Europe, Glucocorticoids, Lumbar Vertebrae and Osteoporosis.

What This Means in Plain Language

The paper is a randomized and open-label study of Teriparatide over 18 months.

The publication is from 2013 (Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research), a journal based in England.

More context: the Teriparatide compound page, all human trials.